市場調査レポート
商品コード
1451616
避妊薬市場レポート:製品、年齢層、流通チャネル、地域別、2024-2032Contraceptive Drugs Market Report by Product, Age Group, Distribution Channel, and Region 2024-2032 |
|||||||
カスタマイズ可能
|
避妊薬市場レポート:製品、年齢層、流通チャネル、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2~3営業日
|
世界の避妊薬市場規模は2023年に158億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて4.9%の成長率(CAGR)を示し、2032年までに245億米ドルに達すると予測しています。
避妊薬とは、妊娠を予防し出生率をコントロールするために使用される避妊薬のことです。エストロゲンとプロゲスチンという2種類の女性ホルモンを用いて合成され、排卵を防ぐ。また、これらのホルモンは子宮頸管粘液を濃くしたり、子宮内膜を変化させたりして、受精や着床のために精子が子宮頸管に入るのを妨げます。避妊薬は、にきび、骨菲薄化、卵巣がん、卵管や子宮の感染症、月経前症候群(PMS)のリスクを下げるのを助ける。その結果、出産適齢期の女性の望まない妊娠を抑制するために、ヘルスケア専門医によって投与されます。現在、主に経口剤、注射剤、外用剤が販売されています。
世界の避妊薬市場を牽引する主な要因の一つは、家族計画に関する消費者の意識の高まり、人口の増加、意図しない妊娠の増加です。これに伴い、最適な安全性、より良い臨床結果など複数の利点があることから、医療従事者が従来の方法よりも最新の避妊法に傾倒していることも成長を促す要因となっています。さらに、食品医薬品局(FDA)のような複数の規制機関による新薬の頻繁な承認が、市場の成長を支えています。さらに、膣内のpHレベルを維持することで精子が生存しにくい環境を作り出すゼラチンカプセルや非ホルモン性膣ゲルの登場が、市場の成長を促しています。これとは別に、継続的な研究開発(R&D)活動や、非政府組織(NGO)や保健機関が避妊技術や女性の健康、性的ウェルネスについて消費者を啓発するために行っている好意的な取り組みが、市場の成長を積極的に後押ししています。
The global contraceptive drugs market size reached US$ 15.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032.
Contraceptive drugs refer to birth control medications that are used to prevent pregnancy and control the birth rate. They are synthetically formulated using two female hormones, namely estrogen and progestin, which prevent ovulation. These hormones also thicken cervical mucus or alter the womb lining to prohibit the entrance of sperm into the cervix for fertilization and implantation. Contraceptive drugs assist in lowering the risks of acne, bone thinning, ovarian cancer, infections in the fallopian tubes and uterus, and premenstrual syndrome (PMS). As a result, they are administered by healthcare practitioners to inhibit unwanted pregnancy amongst women of childbearing age. At present, they are mainly available in oral, injectable, and topical formulations.
One of the key factors driving the global contraceptive drugs market is the rising consumer consciousness regarding family planning, the increasing population, and the rising instances of unintended pregnancies. In line with this, the shifting inclination of healthcare practitioners toward modern contraceptive methods over conventional procedures, owing to their multiple benefits, including optimal safety, and better clinical outcomes, are acting as another growth-inducing factor. Additionally, the frequent approvals of novel medications by several regulatory bodies, such as the food and drug administration (FDA), are supporting the market growth. Moreover, the advent of gelatin capsules and non-hormonal vaginal gels that create an inhospitable environment for sperm to sustain by maintaining vagina pH levels is impelling the market growth. Apart from this, continuous research and development (R&D) activities and the favorable initiatives undertaken by non-governmental organizations (NGOs) and health agencies to sensitize consumers about contraception techniques, women's health, and sexual wellness are positively augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, age group and distribution channel.
Oral Contraceptive Pills
Injectable Contraceptives
Topical Contraceptives
15-24 years
25-34 years
35-44 years
Above 44 years
Retail Pharmacy
Hospital Pharmacy
Clinics
Online Channel
Public Channel and NGOs
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and Viatris Inc.